{"id":4636,"date":"2025-05-03T21:16:05","date_gmt":"2025-05-03T21:16:05","guid":{"rendered":"https:\/\/fehv.org\/?p=4636"},"modified":"2025-05-03T21:16:07","modified_gmt":"2025-05-03T21:16:07","slug":"efimosfermin-alfa-new-drug-for-fatty-liver","status":"publish","type":"post","link":"https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/","title":{"rendered":"Efimosfermin-alfa: New drug for fatty liver"},"content":{"rendered":"\n

As we have mentioned on several occasions, numerous new drugs are being investigated for the treatment of fatty liver disease. Preliminary analyses have shown that efimosfermin-alfa reduces liver fat, improves liver inflammation, and decreases fibrosis. The results of a new study with this drug have recently been reported. The advantage of this drug is that it only needs to be administered once monthly by subcutaneous injection<\/strong>.<\/p>\n\n\n\n

The study included 84 patients with fatty liver disease<\/a><\/strong> (diagnosed by liver biopsy) with stage F2\/F3 fibrosis (the highest stage of fibrosis is F4, which corresponds to cirrhosis). Forty-three of the patients received 300 mg of efimosfermin-alfa once per month for 24 weeks, and the remaining 41 patients received placebo. At the end of treatment, it was found that fibrosis decreased in 45% of patients treated with efimosfermin<\/strong>, compared to 20% of those treated with placebo. Furthermore, inflammation and liver fat were eliminated in 67% of patients receiving efimosfermin-alfa, compared to 29% in the placebo group. Side effects were mild or moderate and included nausea, diarrhea, and vomiting.<\/p>\n\n\n\n

In conclusion, efimosfermin-alfa is a drug that offers good promise for the treatment of fatty liver disease <\/strong>and has the significant advantage of being administered only once a month. However, as we always say, we must wait for further studies with a much larger number of patients to determine the true efficacy of this drug in the treatment of fatty liver disease.<\/p>\n","protected":false},"excerpt":{"rendered":"Efimosfermin-alfa shows promise as a treatment for fatty liver disease, improving fibrosis and inflammation with monthly dosing, according to early clinical study results.","protected":false},"author":1,"featured_media":4634,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[623,621,624],"tags":[],"class_list":["post-4636","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fatty-liver","category-news","category-treatments"],"acf":[],"yoast_head":"\nEfimosfermin-alfa: New drug for fatty liver - Cl\u00ednica FEHV<\/title>\n<meta name=\"description\" content=\"The drug efimosfermin-alfa for fatty liver disease shows promising results, reducing fibrosis, inflammation, and liver fat.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Efimosfermin-alfa: New drug for fatty liver\" \/>\n<meta property=\"og:description\" content=\"The drug efimosfermin-alfa for fatty liver disease shows promising results, reducing fibrosis, inflammation, and liver fat.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/\" \/>\n<meta property=\"og:site_name\" content=\"Cl\u00ednica FEHV\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/clinicaFEHV\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-03T21:16:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-03T21:16:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fehv.org\/wp-content\/uploads\/2025\/05\/efimosfermin-higado-graso.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1264\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ifranco\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ifranco\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/efimosfermin-alfa-new-drug-for-fatty-liver\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/efimosfermin-alfa-new-drug-for-fatty-liver\\\/\"},\"author\":{\"name\":\"ifranco\",\"@id\":\"https:\\\/\\\/fehv.org\\\/#\\\/schema\\\/person\\\/5e92ddd4a04516dab21fb5b6fa90b777\"},\"headline\":\"Efimosfermin-alfa: New drug for fatty liver\",\"datePublished\":\"2025-05-03T21:16:05+00:00\",\"dateModified\":\"2025-05-03T21:16:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/efimosfermin-alfa-new-drug-for-fatty-liver\\\/\"},\"wordCount\":235,\"publisher\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/efimosfermin-alfa-new-drug-for-fatty-liver\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/efimosfermin-higado-graso.jpg\",\"articleSection\":[\"Fatty liver\",\"News\",\"Treatments\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/efimosfermin-alfa-new-drug-for-fatty-liver\\\/\",\"url\":\"https:\\\/\\\/fehv.org\\\/en\\\/efimosfermin-alfa-new-drug-for-fatty-liver\\\/\",\"name\":\"Efimosfermin-alfa: New drug for fatty liver - Cl\u00ednica FEHV\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/efimosfermin-alfa-new-drug-for-fatty-liver\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/efimosfermin-alfa-new-drug-for-fatty-liver\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/efimosfermin-higado-graso.jpg\",\"datePublished\":\"2025-05-03T21:16:05+00:00\",\"dateModified\":\"2025-05-03T21:16:07+00:00\",\"description\":\"The drug efimosfermin-alfa for fatty liver disease shows promising results, reducing fibrosis, inflammation, and liver fat.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/efimosfermin-alfa-new-drug-for-fatty-liver\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fehv.org\\\/en\\\/efimosfermin-alfa-new-drug-for-fatty-liver\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/efimosfermin-alfa-new-drug-for-fatty-liver\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/efimosfermin-higado-graso.jpg\",\"contentUrl\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/efimosfermin-higado-graso.jpg\",\"width\":1920,\"height\":1264,\"caption\":\"Nuevo medicamento para el higado graso\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/efimosfermin-alfa-new-drug-for-fatty-liver\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fehv.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Efimosfermin-alfa: New drug for fatty liver\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fehv.org\\\/#website\",\"url\":\"https:\\\/\\\/fehv.org\\\/\",\"name\":\"Cl\u00ednica FEHV\",\"description\":\"Web de la Cl\u00ednica de la Fundaci\u00f3n para el Estudio de las Hepatitis Virales\",\"publisher\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fehv.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fehv.org\\\/#organization\",\"name\":\"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV\",\"url\":\"https:\\\/\\\/fehv.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fehv.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2021\\\/03\\\/logo_fib-4.png\",\"contentUrl\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2021\\\/03\\\/logo_fib-4.png\",\"width\":47,\"height\":73,\"caption\":\"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV\"},\"image\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/clinicaFEHV\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fehv.org\\\/#\\\/schema\\\/person\\\/5e92ddd4a04516dab21fb5b6fa90b777\",\"name\":\"ifranco\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g\",\"caption\":\"ifranco\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Efimosfermin-alfa: New drug for fatty liver - Cl\u00ednica FEHV","description":"The drug efimosfermin-alfa for fatty liver disease shows promising results, reducing fibrosis, inflammation, and liver fat.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/","og_locale":"en_US","og_type":"article","og_title":"Efimosfermin-alfa: New drug for fatty liver","og_description":"The drug efimosfermin-alfa for fatty liver disease shows promising results, reducing fibrosis, inflammation, and liver fat.","og_url":"https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/","og_site_name":"Cl\u00ednica FEHV","article_publisher":"https:\/\/www.facebook.com\/clinicaFEHV\/","article_published_time":"2025-05-03T21:16:05+00:00","article_modified_time":"2025-05-03T21:16:07+00:00","og_image":[{"width":1920,"height":1264,"url":"https:\/\/fehv.org\/wp-content\/uploads\/2025\/05\/efimosfermin-higado-graso.jpg","type":"image\/jpeg"}],"author":"ifranco","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ifranco","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/#article","isPartOf":{"@id":"https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/"},"author":{"name":"ifranco","@id":"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777"},"headline":"Efimosfermin-alfa: New drug for fatty liver","datePublished":"2025-05-03T21:16:05+00:00","dateModified":"2025-05-03T21:16:07+00:00","mainEntityOfPage":{"@id":"https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/"},"wordCount":235,"publisher":{"@id":"https:\/\/fehv.org\/#organization"},"image":{"@id":"https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/#primaryimage"},"thumbnailUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2025\/05\/efimosfermin-higado-graso.jpg","articleSection":["Fatty liver","News","Treatments"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/","url":"https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/","name":"Efimosfermin-alfa: New drug for fatty liver - Cl\u00ednica FEHV","isPartOf":{"@id":"https:\/\/fehv.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/#primaryimage"},"image":{"@id":"https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/#primaryimage"},"thumbnailUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2025\/05\/efimosfermin-higado-graso.jpg","datePublished":"2025-05-03T21:16:05+00:00","dateModified":"2025-05-03T21:16:07+00:00","description":"The drug efimosfermin-alfa for fatty liver disease shows promising results, reducing fibrosis, inflammation, and liver fat.","breadcrumb":{"@id":"https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/#primaryimage","url":"https:\/\/fehv.org\/wp-content\/uploads\/2025\/05\/efimosfermin-higado-graso.jpg","contentUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2025\/05\/efimosfermin-higado-graso.jpg","width":1920,"height":1264,"caption":"Nuevo medicamento para el higado graso"},{"@type":"BreadcrumbList","@id":"https:\/\/fehv.org\/en\/efimosfermin-alfa-new-drug-for-fatty-liver\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fehv.org\/en\/"},{"@type":"ListItem","position":2,"name":"Efimosfermin-alfa: New drug for fatty liver"}]},{"@type":"WebSite","@id":"https:\/\/fehv.org\/#website","url":"https:\/\/fehv.org\/","name":"Cl\u00ednica FEHV","description":"Web de la Cl\u00ednica de la Fundaci\u00f3n para el Estudio de las Hepatitis Virales","publisher":{"@id":"https:\/\/fehv.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fehv.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fehv.org\/#organization","name":"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV","url":"https:\/\/fehv.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fehv.org\/#\/schema\/logo\/image\/","url":"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png","contentUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png","width":47,"height":73,"caption":"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV"},"image":{"@id":"https:\/\/fehv.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/clinicaFEHV\/"]},{"@type":"Person","@id":"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777","name":"ifranco","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g","caption":"ifranco"}}]}},"_links":{"self":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/4636","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/comments?post=4636"}],"version-history":[{"count":1,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/4636\/revisions"}],"predecessor-version":[{"id":4637,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/4636\/revisions\/4637"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/media\/4634"}],"wp:attachment":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/media?parent=4636"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/categories?post=4636"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/tags?post=4636"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}